Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYAdaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood CancersPREV STORYMacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results